WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal quarter ended September 30, 2024. “We are continuing to explore multiple strategic alternatives to further unlock shareholder value. These may include finding a partner for one or more of our assets, a sale o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Ordinary Shares, no par value PRTG Nasdaq Capital Market FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURI ...

Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Nine Months Ended December 31, 2023 (Unaudited – Prepared by Management as of February 28, 2024) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements | Index | Page | | --- | --- | | Notice to Reader | F-1 | | Condensed Consolidated Interim Statements of Financial Position | | | As of December 31, 2023 (Unaudited) and March 31, 2023 | F-2 | | Condensed Consolidated Inter ...

Condensed Consolidated Interim Financial Statements For the Three and Six Months Ended September 30, 2023 (Unaudited – Prepared by Management as of November 28, 2023) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements | Index | Page | | --- | --- | | Notice to Reader | F-1 | | Condensed Consolidated Interim Statements of Financial Position | | | As of September 30, 2023 (Unaudited) and March 31, 2023 | F-2 | | Condensed Consolidated Interim Statements of Operations and O ...

Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three Months Ended June 30, 2023 (Unaudited – Prepared by Management as of August 29, 2023) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements | Index | Page | | --- | --- | | Notice to Reader | F-1 | | Condensed Consolidated Interim Statements of Financial Position | | | As of June 30, 2023 (Unaudited) and March 31, 2023 | F-2 | | Condensed Consolidated Interim Statements of Op ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of eve ...

Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Nine Months Ended December 31, 2022 (Unaudited – Prepared by Management as of March 1, 2023) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements | Index | Page | | --- | --- | | Notice to Reader | F-1 | | Condensed Consolidated Interim Statements of Financial Position | | | As of December 31, 2022 (Unaudited) and March 31, 2022 | F-2 | | Condensed Consolidated Interim S ...

Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Six Months Ended September 30, 2022 (Unaudited – Prepared by Management) as of November 29, 2022 (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements | Index | Page | | --- | --- | | Notice to Reader | F-1 | | Condensed Consolidated Interim Statements of Financial Position | | | As of September 30, 2022 (Unaudited) and March 31, 2022 | F-2 | | Condensed Consolidated Inte ...

Exhibit 99.1 For the Three Months Ended June 30, 2022 Portage Biotech Inc. (Unaudited – Prepared by Management) Condensed Consolidated Interim Financial Statements (U.S. Dollars) | Index | Page | | --- | --- | | Notice to Reader | F-1 | | Condensed Consolidated Interim Statements of Financial Position | F-2 | | As of June 30, 2022 (Unaudited) and March 31, 2022 | | | Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) | F-3 | | Three months ended June 30 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of eve ...